Actively Recruiting
Identification of Mechanisms and Biomarkers Predictive of Tolerance in Children With Food Allergies Comparing Oral Immunotherapy and Natural Evolution
Led by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Updated on 2026-02-27
68
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
Sponsors
F
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Lead Sponsor
F
Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating food allergies to cow's milk and hen's egg proteins, which are common causes of food allergies in early childhood and can lead to serious reactions, reduced quality of life, and health costs. While many children outgrow these allergies naturally by age 5, some continue to have allergies into adolescence. This study aims to compare natural allergy resolution with oral immunotherapy (OIT), a treatment that gradually introduces small amounts of the allergenic food to increase tolerance, to better understand which approach is more effective for children with mild to moderate allergies who are older than 6 years. The study includes two groups of children aged 4 to 17 years with cow's milk or hen's egg allergies. One group follows the standard care of avoiding the allergenic food, while the other undergoes OIT to build tolerance by taking increasing doses of milk or egg protein. The OIT group consists of children who have achieved full or partial desensitization after about 7 months of treatment. Both groups will be followed for up to 29 months to track their allergy status and immune responses. Participants will have regular assessments including food challenges to test tolerance, questionnaires about quality of life, and monitoring of allergic reactions. Researchers will compare how many children in each group achieve sustained unresponsiveness, meaning they can tolerate the food even after a period of avoidance. They will also evaluate quality of life changes and the safety of the treatments. The study will last about two years for the OIT group and slightly longer for the avoidance group, with ongoing follow-up to understand long-term outcomes.
CONDITIONS
Brief Title
Tolerance Results and Immune Mechanisms in Cow´s Milk and/or Hen´s Egg Allergic Children Following Natural Evolution or Oral Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cow's milk and/or hen's egg allergic patients aged 4 to 10 years for the natural evolution cohort
- Specific IgE levels to milk or egg extracts between 0.35 to 35 kUA/L
- Positive open food challenge with milk or egg showing moderate or higher allergic reaction
- Mild to moderate food allergy severity per DEFASE score (<13 points)
- Signed informed consent
- Patients undergoing oral immunotherapy who have achieved full or partial desensitization by month 7 in the compITO study
- Signed informed consent for oral immunotherapy cohort
You will not qualify if you...
- Positive reaction with eliciting dose below target thresholds on entry food challenge
- Desire or medical need to start oral immunotherapy within 29 months of study entry
- No allergic reaction greater than mild on baseline challenge for maximum cumulative doses
- Immunological diseases or immunomodulatory therapies
- Severe atopic dermatitis per SCORAD
- Severe allergy per DEFASE score (≥13)
- Moderate-to-severe airway obstruction or poorly controlled asthma
- Previous oral immunotherapy for another food
- Recent treatment with subcutaneous or sublingual aeroallergen immunotherapy
- Presence or suspicion of eosinophilic esophagitis
- Non-IgE-mediated milk or egg allergy
- Pregnancy
- Significant medical comorbidities (renal, hepatic, cardiac insufficiency, active infections, cancers)
- Inability to provide informed consent or communication barriers
- Failure or withdrawal from compITO study for oral immunotherapy cohort
- Uncontrolled atopic dermatitis or asthma, eosinophilic esophagitis, pregnancy, or significant comorbidities at enrollment for oral immunotherapy cohort
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months
Participants undergo either oral immunotherapy with incremental doses of the allergenic food or follow allergenic food avoidance as standard care.
Regular visits throughout treatment duration
Duration - Up to 5 months post-treatment for natural evolution cohort
Participants are monitored to assess tolerance development and immune mechanisms after treatment or natural evolution.
Periodic visits until month 29 for natural evolution cohort; until month 24 for oral immunotherapy cohort
Trial Site Locations
Total: 1 location
1
Hospital Infantil Universitario Niño Jesús. Avenida de Menéndez Pelayo, número 65
Madrid, Madrid, Spain, 28009
Actively Recruiting
Research Team
P
Pablo Rodríguez del Río, MD PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here